
Dr Gayatri Mittal
Consultant Rheumatologist
About Gayatri Mittal
Specialty: Consultant Rheumatologist, with special clinical interests in inflammatory arthritis, gout and hypermobility
Conditions seen: spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, inflammatory arthritis, gout, hypermobility, EDS, arthritis, osteoporosis
Tests, treatments and procedures: zoledronate infusion; specialist clinics in spondyloarthritis, psoriatic arthritis and hypermobility
Often consulted by patients with: inflammatory arthritis including spondyloarthritis, ankylosing spondylitis and psoriatic arthritis; gout; joint hypermobility
Patient ages seen: 18+
Also: clinical lead for biologic and ankylosing spondylitis services at the Royal National Orthopaedic Hospital, Stanmore; Honorary Associate Professor at University College London; clinical excellence awards in 2016 and 2018
Language: English
Dr Gayatri Mittal is a Consultant Rheumatologist at Welbeck’s Rheumatology centre in London. She manages a broad range of rheumatological conditions, with particular clinical interests in inflammatory arthritis, gout and hypermobility. Her practice also includes Ehlers-Danlos syndromes (EDS) and osteoporosis, for which treatment may include zoledronate infusion.
Alongside her work at Welbeck, Dr Mittal is a Consultant Rheumatologist at the Royal National Orthopaedic Hospital (RNOH) in Stanmore, where she is clinical lead for the biologic and ankylosing spondylitis services, and conducts specialist clinics in spondyloarthritis, psoriatic arthritis and hypermobility.
Dr Mittal is also an Honorary Associate Professor at University College London. Her current research focuses on the design and development of targeted intra-articular therapies for arthritis, while her published work spans areas including inflammatory disorders, interleukin-17 biology and anti-tumour necrosis factor therapy in early rheumatoid arthritis.
Her specialist training in the UK included the North East Thames rheumatology rotation, a Clinical Research Fellowship in Bangor, North Wales, and a PhD at the Bone and Joint Research Unit in London. Before moving to the UK in 2002, she worked as a Senior Registrar in Rheumatology at a private tertiary centre in Mumbai, India. She received clinical excellence awards in 2016 and 2018.
Expertise
- Spondyloarthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Gout
- Hypermobility
- EDS
- Rheumatoid Arthritis
- Inflammatory Arthritis
Overview
- Age of patients seen
- 18+
- Qualifications
Dr Mittal's specialist training in the UK included the North East Thames rheumatology rotation, a Clinical Research Fellowship at Bangor in North Wales, and a PhD at the Bone and Joint Research Unit in London. Before coming to the UK in 2002 she worked as a Senior Registrar in Rheumatology at a private tertiary centre in Mumbai, India. She holds an appointment as Honorary Associate Professor at University College London and is clinical lead for biologic and ankylosing spondylitis services at the Royal National Orthopaedic Hospital, Stanmore.
Qualifications:
PhD — Bone and Joint Research Unit, London
- Languages spoken
- English
- Online profiles
- Research highlights
Dr Mittal’s current research focuses on the design and development of targeted intra-articular therapies for arthritis – treatments delivered directly into the joint. Her published work spans targeted therapies for inflammatory disorders, interleukin-17 biology, anti-tumour necrosis factor therapy in rheumatoid arthritis and the development of virtual pain management services. Her PhD was undertaken at the Bone and Joint Research Unit in London, and she holds an honorary academic appointment at University College London.
Key publications:
Rapid design and implementation of a virtual pain management programme due to COVID-19: a quality improvement initiative. Br J Pain. 2022;16(2):191–202. DOI: 10.1177/20494637211039252
Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020;6(2):e001306. DOI: 10.1136/rmdopen-2020-001306
Latent cytokines for targeted therapy of inflammatory disorders. Expert Opin Drug Deliv. 2014;11(1):101–110. DOI: 10.1517/17425247.2014.863872
Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β. Expert Opin Drug Deliv. 2014;11(1):5–16. DOI: 10.1517/17425247.2013.839655
Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr. 2006;84(6):1463–1472. DOI: 10.1093/ajcn/84.6.1463
- Professional memberships
Royal College of Physicians (RCP)
British Society for Rheumatology (BSR)
- Certifications and Awards
Clinical excellence award (2016)
Clinical excellence award (2018)
Consultations and services
Appointments are available at 1 Welbeck Street, Marylebone, London W1G 0AR.
Enquire online or call 020 3653 2002.
- Self-pay available from £350
- Health insurance
- 40 mins consultation
- Self-pay available from £200
- Health insurance
- 20 mins consultation
Insurers covered
Tests & treatments
Conditions & symptoms
Locations
Loading
Frequently asked questions
Dr Mittal treats a broad range of rheumatological conditions, with particular clinical interests in inflammatory arthritis, gout and hypermobility. Her expertise includes spondyloarthritis, ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis, as well as Ehlers-Danlos syndromes (EDS) and osteoporosis.
Yes. Inflammatory arthritis is one of Dr Mittal’s main clinical interests. Her expertise includes spondyloarthritis, ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis, and she is clinical lead for the biologic and ankylosing spondylitis services at the Royal National Orthopaedic Hospital.
Yes, hypermobility is one of Dr Mittal’s special clinical interests, and her expertise also includes Ehlers-Danlos syndromes (EDS). Alongside her work at Welbeck, she conducts a specialist hypermobility clinic at the Royal National Orthopaedic Hospital in Stanmore.
Yes. Dr Mittal offers zoledronate infusion for osteoporosis when clinically appropriate. Whether this treatment is suitable for you will be determined following assessment.

